|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCT5 |
Gene summary for CCT5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCT5 | Gene ID | 22948 |
| Gene name | chaperonin containing TCP1 subunit 5 | |
| Gene Alias | CCT-epsilon | |
| Cytomap | 5p15.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B4DX08 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22948 | CCT5 | GSM4909282 | Human | Breast | IDC | 2.85e-20 | 5.90e-01 | -0.0288 |
| 22948 | CCT5 | GSM4909285 | Human | Breast | IDC | 4.43e-23 | 6.30e-01 | 0.21 |
| 22948 | CCT5 | GSM4909286 | Human | Breast | IDC | 1.57e-03 | -6.90e-02 | 0.1081 |
| 22948 | CCT5 | GSM4909288 | Human | Breast | IDC | 3.72e-04 | 3.12e-01 | 0.0988 |
| 22948 | CCT5 | GSM4909293 | Human | Breast | IDC | 9.82e-03 | -1.12e-01 | 0.1581 |
| 22948 | CCT5 | GSM4909296 | Human | Breast | IDC | 2.19e-11 | -3.38e-01 | 0.1524 |
| 22948 | CCT5 | GSM4909297 | Human | Breast | IDC | 3.63e-07 | -8.96e-02 | 0.1517 |
| 22948 | CCT5 | GSM4909301 | Human | Breast | IDC | 2.05e-04 | -2.72e-01 | 0.1577 |
| 22948 | CCT5 | GSM4909307 | Human | Breast | IDC | 6.30e-06 | -2.84e-01 | 0.1569 |
| 22948 | CCT5 | GSM4909311 | Human | Breast | IDC | 1.89e-25 | -2.72e-01 | 0.1534 |
| 22948 | CCT5 | GSM4909312 | Human | Breast | IDC | 1.01e-06 | -4.73e-02 | 0.1552 |
| 22948 | CCT5 | GSM4909313 | Human | Breast | IDC | 6.29e-05 | -2.99e-01 | 0.0391 |
| 22948 | CCT5 | GSM4909318 | Human | Breast | IDC | 3.11e-09 | 7.13e-01 | 0.2031 |
| 22948 | CCT5 | GSM4909319 | Human | Breast | IDC | 8.51e-27 | -3.80e-01 | 0.1563 |
| 22948 | CCT5 | GSM4909320 | Human | Breast | IDC | 1.30e-02 | -3.16e-01 | 0.1575 |
| 22948 | CCT5 | GSM4909321 | Human | Breast | IDC | 9.26e-09 | -1.47e-01 | 0.1559 |
| 22948 | CCT5 | brca1 | Human | Breast | Precancer | 8.88e-31 | 6.44e-01 | -0.0338 |
| 22948 | CCT5 | brca2 | Human | Breast | Precancer | 2.36e-11 | 4.02e-01 | -0.024 |
| 22948 | CCT5 | brca3 | Human | Breast | Precancer | 4.68e-05 | 3.82e-01 | -0.0263 |
| 22948 | CCT5 | M2 | Human | Breast | IDC | 1.03e-18 | 7.91e-01 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003164720 | Oral cavity | OSCC | regulation of protein stability | 193/7305 | 298/18723 | 1.30e-19 | 1.95e-17 | 193 |
| GO:190382920 | Oral cavity | OSCC | positive regulation of cellular protein localization | 179/7305 | 276/18723 | 2.20e-18 | 2.41e-16 | 179 |
| GO:190495119 | Oral cavity | OSCC | positive regulation of establishment of protein localization | 196/7305 | 319/18723 | 2.89e-16 | 2.20e-14 | 196 |
| GO:000961515 | Oral cavity | OSCC | response to virus | 215/7305 | 367/18723 | 1.63e-14 | 9.41e-13 | 215 |
| GO:00330448 | Oral cavity | OSCC | regulation of chromosome organization | 123/7305 | 187/18723 | 9.87e-14 | 5.17e-12 | 123 |
| GO:005105210 | Oral cavity | OSCC | regulation of DNA metabolic process | 207/7305 | 359/18723 | 4.45e-13 | 2.17e-11 | 207 |
| GO:005082120 | Oral cavity | OSCC | protein stabilization | 122/7305 | 191/18723 | 2.69e-12 | 1.09e-10 | 122 |
| GO:190018210 | Oral cavity | OSCC | positive regulation of protein localization to nucleus | 66/7305 | 87/18723 | 2.74e-12 | 1.10e-10 | 66 |
| GO:190018015 | Oral cavity | OSCC | regulation of protein localization to nucleus | 93/7305 | 136/18723 | 3.46e-12 | 1.35e-10 | 93 |
| GO:005105414 | Oral cavity | OSCC | positive regulation of DNA metabolic process | 126/7305 | 201/18723 | 8.12e-12 | 3.01e-10 | 126 |
| GO:000072316 | Oral cavity | OSCC | telomere maintenance | 85/7305 | 131/18723 | 1.72e-09 | 4.09e-08 | 85 |
| GO:00718979 | Oral cavity | OSCC | DNA biosynthetic process | 106/7305 | 180/18723 | 4.86e-08 | 8.95e-07 | 106 |
| GO:003220410 | Oral cavity | OSCC | regulation of telomere maintenance | 55/7305 | 80/18723 | 6.67e-08 | 1.19e-06 | 55 |
| GO:00345023 | Oral cavity | OSCC | protein localization to chromosome | 60/7305 | 92/18723 | 3.17e-07 | 4.79e-06 | 60 |
| GO:200027817 | Oral cavity | OSCC | regulation of DNA biosynthetic process | 67/7305 | 106/18723 | 3.85e-07 | 5.75e-06 | 67 |
| GO:000700410 | Oral cavity | OSCC | telomere maintenance via telomerase | 46/7305 | 69/18723 | 3.00e-06 | 3.66e-05 | 46 |
| GO:200057316 | Oral cavity | OSCC | positive regulation of DNA biosynthetic process | 44/7305 | 66/18723 | 4.91e-06 | 5.57e-05 | 44 |
| GO:200125216 | Oral cavity | OSCC | positive regulation of chromosome organization | 52/7305 | 82/18723 | 6.56e-06 | 7.24e-05 | 52 |
| GO:19048726 | Oral cavity | OSCC | regulation of telomerase RNA localization to Cajal body | 16/7305 | 18/18723 | 1.75e-05 | 1.71e-04 | 16 |
| GO:001083316 | Oral cavity | OSCC | telomere maintenance via telomere lengthening | 50/7305 | 81/18723 | 2.87e-05 | 2.64e-04 | 50 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCT5 | SNV | Missense_Mutation | rs762786367 | c.1046N>T | p.Thr349Ile | p.T349I | P48643 | protein_coding | deleterious(0) | possibly_damaging(0.71) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| CCT5 | SNV | Missense_Mutation | c.1031G>T | p.Arg344Met | p.R344M | P48643 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCT5 | SNV | Missense_Mutation | c.1018C>T | p.Arg340Trp | p.R340W | P48643 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CCT5 | SNV | Missense_Mutation | c.1018N>T | p.Arg340Trp | p.R340W | P48643 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| CCT5 | SNV | Missense_Mutation | rs768768696 | c.1006G>A | p.Ala336Thr | p.A336T | P48643 | protein_coding | tolerated(0.07) | benign(0.325) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCT5 | SNV | Missense_Mutation | novel | c.359N>T | p.Ala120Val | p.A120V | P48643 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CCT5 | SNV | Missense_Mutation | rs768768696 | c.1006N>A | p.Ala336Thr | p.A336T | P48643 | protein_coding | tolerated(0.07) | benign(0.325) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CCT5 | SNV | Missense_Mutation | c.338N>A | p.Ala113Asp | p.A113D | P48643 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| CCT5 | SNV | Missense_Mutation | novel | c.819N>G | p.Asp273Glu | p.D273E | P48643 | protein_coding | tolerated(1) | benign(0.019) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| CCT5 | SNV | Missense_Mutation | c.1400N>A | p.Gly467Asp | p.G467D | P48643 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |